Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: testing (1000), conducting tests (149)

Inflammatory bowel disease service - patient information

Description: If you have ulcerative colitis, Crohn's disease or another IBD, you will be cared for by our IBD service team.
Url: /Media/UHS-website-2019/Patientinformation/Digestionandurinaryhealth/Inflammatory-bowel-disease-service-1647-PIL.pdf

Bevacizumab (15) Carboplatin-Paclitaxel (21 day)

Description: Chemotherapy Protocol GYNAECOLOGICAL CANCER BEVACIZUMAB (15)-CARBOPLATIN (AUC5)-PACLITAXEL (21 day) Regimen • Cervix-Bevacizumab (15)-Carboplatin (AUC5)-Paclitaxel (21 day) Indication
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Cervical-cancer/Bevacizumab-15-Carboplatin-Paclitaxel-21-day.pdf

RIPCORD Privacy Notice UHS v5

Description: This is a PRIVACY NOTICE for patients who took part in the RIPCORD 2 study Chief Investigator: Professor Nicholas Curzen, University
Url: /Media/Southampton-Clinical-Research/Downloads/RIPCORD-Privacy-Notice-UHS-v5.pdf

Annual-report-2017-18

Description: ANNUAL REPORT AND ACCOUNTS 2017/18 incorporating the quality account 2017/18 Presented to Parliament pursuant to Schedule 7, paragraph 25
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/annual-report-2017-181.pdf

Docetaxel

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) DOCETAXEL (75) Regimen NSCLC – Docetaxel (75) Indication Second line therapy of stage IIIB
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Docetaxelver12.pdf

Targeting-Shared-Mechanisms-Call-1

Description: Call for Applications: Targeting shared mechanisms in immune-mediated inflammatory diseases Introduction and rationale There are more than 80 autoimmune conditions
Url: /Media/Southampton-Clinical-Research/Downloads/Targeting-Shared-Mechanisms-Call-1.pdf

Jennifer Allison, Matron

Description: NIHR Southampton Clinical Research Facility Auto Generated Title Jennifer Allison is Matron of the NIHR Southampton Clinical Research Facility. She is
Url: /ClinicalResearchinSouthampton/Our-people/Clinical-research-facility-people/Jennifer-Allison-Matron.aspx

DA_3+8

Description: Regimen Chemotherapy Protocol ACUTE MYELOID LEUKAEMIA DA (3+8)–Cytarabine-Daunorubicin In-Patient Regimen • Acute Myeloid Leukaemia – InP-DA (3+8
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/DA-3-8.pdf

DA_2+5

Description: Chemotherapy Protocol ACUTE MYELOID LEUKAEMIA DA (2 + 5) – Cytarabine-Daunorubicin In-Patient Regimen Regimen • Acute Myeloid Leukaemia – InP-DA (2+5
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/DA-2-5.pdf

Niraparib

Description: Chemotherapy Protocol GYNAECOLOGICAL CANCERS Regimen NIRAPARIB • Ovarian Cancer – Niraparib Indication • Niraparib is recommended as maintenance treatment in patients with relapsed, platinum
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/Niraparib.pdf

201 to 210 of 517

Previous … 19 20 21 22 23 … Next